Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Change in Cash (2022 - 2025)

Historic Change in Cash for Addex Therapeutics (ADXN) over the last 4 years, with Q2 2025 value amounting to $604.8 billion.

  • Addex Therapeutics' Change in Cash fell 7305.47% to $604.8 billion in Q2 2025 from the same period last year, while for Jun 2025 it was -$624.1 billion, marking a year-over-year increase of 7806.52%. This contributed to the annual value of -$708648.2 for FY2024, which is 7672.66% up from last year.
  • Per Addex Therapeutics' latest filing, its Change in Cash stood at $604.8 billion for Q2 2025, which was down 7305.47% from -$556.9 billion recorded in Q1 2025.
  • Addex Therapeutics' 5-year Change in Cash high stood at $2244.6 billion for Q2 2024, and its period low was -$2764.5 billion during Q3 2023.
  • Over the past 4 years, Addex Therapeutics' median Change in Cash value was -$4.8 million (recorded in 2022), while the average stood at -$216.9 billion.
  • Over the last 5 years, Addex Therapeutics' Change in Cash had its largest YoY gain of 695649518.01% in 2023, and its largest YoY loss of 17814012700.49% in 2023.
  • Addex Therapeutics' Change in Cash (Quarter) stood at -$14.0 million in 2022, then soared by 75.18% to -$3.5 million in 2023, then soared by 82.87% to -$597015.9 in 2024, then skyrocketed by 101305200.1% to $604.8 billion in 2025.
  • Its Change in Cash was $604.8 billion in Q2 2025, compared to -$556.9 billion in Q1 2025 and -$597015.9 in Q4 2024.